Featured Research

from universities, journals, and other organizations

DNA shed by tumors show promise for non-invasive screening, prognosis

Date:
February 19, 2014
Source:
Johns Hopkins Medicine
Summary:
Certain fragments of DNA shed by tumors into the bloodstream can potentially be used to non-invasively screen for early-stage cancers, monitor responses to treatment and help explain why some cancers are resistant to therapies, according to results of an international study. Analyzing blood samples from 640 patients with various cancers, the researchers used digital polymerase chain reaction-based technology to evaluate how well the DNA fragments predicted the presence of tumors in the patients. Investigators say the work provides strong evidence that ctDNA could be used as a “personalized biomarker” test and cancer screening tool.

Certain fragments of DNA shed by tumors into the bloodstream can potentially be used to non-invasively screen for early-stage cancers, monitor responses to treatment and help explain why some cancers are resistant to therapies, according to results of an international study led by Johns Hopkins Kimmel Cancer Center investigators.

Analyzing blood samples from 640 patients with various cancers, the researchers used digital polymerase chain reaction-based technology (a sophisticated method of multiplying and measuring the number DNA molecules) to evaluate how well the DNA fragments predicted the presence of tumors in the patients.

The fragments, known as cell-free circulating tumor DNA (ctDNA), were detected in the blood of more than 75 percent of patients with advanced cancers and in at least half of patients with localized, smaller tumors that had not spread outside of the organ where the cancer originated and still had the potential for cure.

Investigators say the work, published Feb. 19 in the journal Science Translational Medicine, provides strong evidence that ctDNA could be used as a "personalized biomarker" test and cancer screening tool.

"We're already very good at treating and curing cancer when it is localized," says lead study author Chetan Bettegowda, M.D., Ph.D., an assistant professor of oncology and neurological surgery. "But we wanted to develop a non-invasive technology to enhance detection of cancer at an early stage, and we feel this is an exciting starting point for further work using this method."

"The most promising aspect is that ctDNA can identify early-stage cancers," adds one of the study's senior authors, Luis Diaz, M.D., associate professor of oncology and director of the Swim Across America Laboratory at Johns Hopkins.

Among study participants with metastatic cancers, researchers detected ctDNA in 82 percent of patients with solid tumors outside the brain (112 of 136 patients), including more than 75 percent of patients with advanced ovarian, colorectal, bladder, gastroesophageal, pancreatic, breast, hepatocellular, and head and neck cancers, as well as melanomas. Less than 50 percent of patients with medulloblastomas or metastatic cancers of the kidney, prostate or thyroid, and less than 10 percent of patients with gliomas, had detectable ctDNA.

Among 223 patients with localized tumors, researchers detected ctDNA in 55 percent of all patient samples, and in 73 percent of those with colorectal cancer, 57 percent of those with gastroesophageal cancer, 48 percent of those with pancreatic cancer and 50 percent of those with breast adenocarcinoma. Increasing levels of ctDNA correlated with the stage of cancer: 47 percent of patients with Stage I cancers of any type had detectable ctDNA, as did 55 percent of patients with Stage II cancers, 69 percent of patients with Stage III cancers, and 82 percent of patients with Stage IV cancers.

Comparing ctDNA with circulating tumor cells (CTCs), intact cells shed from a primary tumor that circulate in the bloodstream and may lead to metastasis, researchers found that ctDNA was often present in patients without detectable CTCs. They did not identify any cases in which CTCs were detected and ctDNA was absent.

The researchers also studied how accurately the test identified mutations in patients' tumors. They analyzed tumors and blood samples in a separate group of 206 patients with metastatic colorectal cancers, finding that ctDNA correctly identified 87 percent of patients with KRAS gene mutations, meaning that these patients' tumors may be susceptible to a therapy called epidermal growth factor receptor (EGFR) blockade.

In addition, investigators assessed whether ctDNA could provide clues to how cancers build resistance to EGFR blockade therapy in 24 patients who responded to therapy initially but later relapsed. They found that 23 (96 percent) of patients developed one or more mutations in genes involved in a signaling pathway called MAPK, which regulates gene expression and cell survival, among other tasks, and may help cancer cells thrive.

The study "provides a wealth of information on the potential utility and limitations of ctDNA measurements to assess patients with various cancers," the study authors wrote.


Story Source:

The above story is based on materials provided by Johns Hopkins Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. C. Bettegowda, M. Sausen, R. J. Leary, I. Kinde, Y. Wang, N. Agrawal, B. R. Bartlett, H. Wang, B. Luber, R. M. Alani, E. S. Antonarakis, N. S. Azad, A. Bardelli, H. Brem, J. L. Cameron, C. C. Lee, L. A. Fecher, G. L. Gallia, P. Gibbs, D. Le, R. L. Giuntoli, M. Goggins, M. D. Hogarty, M. Holdhoff, S.-M. Hong, Y. Jiao, H. H. Juhl, J. J. Kim, G. Siravegna, D. A. Laheru, C. Lauricella, M. Lim, E. J. Lipson, S. K. N. Marie, G. J. Netto, K. S. Oliner, A. Olivi, L. Olsson, G. J. Riggins, A. Sartore-Bianchi, K. Schmidt, l.-M. Shih, S. M. Oba-Shinjo, S. Siena, D. Theodorescu, J. Tie, T. T. Harkins, S. Veronese, T.-L. Wang, J. D. Weingart, C. L. Wolfgang, L. D. Wood, D. Xing, R. H. Hruban, J. Wu, P. J. Allen, C. M. Schmidt, M. A. Choti, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, N. Papadopoulos, L. A. Diaz. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Science Translational Medicine, 2014; 6 (224): 224ra24 DOI: 10.1126/scitranslmed.3007094

Cite This Page:

Johns Hopkins Medicine. "DNA shed by tumors show promise for non-invasive screening, prognosis." ScienceDaily. ScienceDaily, 19 February 2014. <www.sciencedaily.com/releases/2014/02/140219142357.htm>.
Johns Hopkins Medicine. (2014, February 19). DNA shed by tumors show promise for non-invasive screening, prognosis. ScienceDaily. Retrieved July 26, 2014 from www.sciencedaily.com/releases/2014/02/140219142357.htm
Johns Hopkins Medicine. "DNA shed by tumors show promise for non-invasive screening, prognosis." ScienceDaily. www.sciencedaily.com/releases/2014/02/140219142357.htm (accessed July 26, 2014).

Share This




More Health & Medicine News

Saturday, July 26, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins